EYPT vs XYL · rev $1.2M vs P/E 27, rev $4.46B
Eyepoint Pharmaceuticals Inc (EYPT) versus Xylem Inc (XYL) — a side-by-side from cached financials, not a winner call.
Eyepoint Pharmaceuticals Inc (EYPT) is a biotechnology company listed on NASDAQ.
Xylem Inc (XYL) is a specialty industrial machinery company listed on NYSE.
Latest reported EYPT revenue for 2026-06-30 was $1.2M. Net income was -$179.3M. Revenue was up 72.8% from 2026-03-31 to 2026-06-30. EYPT currently screens at market cap $1.10B.
Latest reported XYL revenue for 2026-06-30 was $4.46B. Net income was $456.0M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
EYPT currently screens at market cap $1.10B. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
Not investment advice. Open the EYPT and XYL stock pages for the full models.
Not investment advice.